Please wait while the formulary information is being retrieved.
LAMIVUDINE-ZIDOVUDINE (LAMIVUDINE/ZIDOVUDINE)
- HIV infection
lamivudine 150 mg-zidovudine 300 mg tablet
- 1 tablet by oral route every 12 hours
150 mg-300 mg tablet
- 1 tablet by oral route every 12 hours
HIV infection
- 1 tablet by oral route 2 times per day
- 1 tablet by oral route every 12 hours
- None
Contraindicated
- Adriamycin
- Adriamycin Pfs
- clozapine
- Clozaril
- Copegus
- Cytovene
- deferiprone
- Doxil
- doxorubicin
- doxorubicin HCl peg-liposomal
- Fazaclo
- Ferriprox
- ganciclovir sodium
- Lipodox
- Lipodox 50
- Moderiba
- Moderiba Dose Pack
- Rebetol
- Ribapak Dose Pack
- Ribasphere
- Ribatab Dose Pack
- ribavirin
- stavudine
- Versacloz
- Virazole
- Zerit
Severe
Moderate
- colchicine-probenecid
- Diskets
- Dolophine
- methadone
- Methadone Intensol
- Methadose
- probenecid
- Acute pancreatitis
- Chronic pancreatitis
- Lactating mother
- Lactic acidosis
- Severe hepatic disease
Contraindicated
- Anemia
- Bone marrow depression
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hepatomegaly
- Myopathy
- Myositis
- Neutropenic disorder
Severe
Moderate
- Disease of liver
- Kidney disease with likely reduction in GFR
- Toxic amblyopia
LAMIVUDINE-ZIDOVUDINE (LAMIVUDINE/ZIDOVUDINE)
- HIV infection
- Leukopenia
- Paresthesia
- Peripheral neuropathy
- Cough
- Diarrhea
- Fatigue
- Headache disorder
- Lipodystrophy associated with HIV
- Malaise
- Musculoskeletal pain
- Nasal congestion
- Nausea
More Frequent
Severe
Less Severe
- None
- Abdominal pain with cramps
- Anorexia
- Arthralgias
- Chills
- Disorder of the digestive system
- Dizziness
- Dyspepsia
- Fever
- General weakness
- Insomnia
- Myalgias
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute pancreatitis
- Anaphylaxis
- Anemia
- Cardiomyopathy
- Dehydration
- Drug-induced hepatitis
- Erythema multiforme
- Heart failure
- Hyperglycemia
- Lactic acidosis
- Lymphadenopathy
- Myopathy
- Neutropenic disorder
- Pure red cell aplasia
- Rhabdomyolysis
- Seizure disorder
- Skin rash
- Splenomegaly
- Steatosis of liver
- Stevens-johnson syndrome
- Stomatitis
- Thrombocytopenic disorder
- Urticaria
- Vasculitis
- Wheezing
Less Severe
- Alopecia
- Gynecomastia
- Hyperpigmentation of oral mucosa
- Muscle weakness
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lamivudine_Zidovudine
Fixed dose combination not recommended for weight < 30 kg.
- 1 Day – 12 Years
- Fixed dose combination not recommended for weight < 30 kg.
Lamivudine
- Severity Level:
2
- Additional Notes: No fda cat;art preg registry data show no increased risk for major birth defects
Zidovudine
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
Lamivudine
Avoid breastfeeding in hiv positive women per cdc
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Avoid breastfeeding in hiv positive women per cdc |
Zidovudine
Avoid breastfeeding in hiv positive women per cdc
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Zidovudine, one of the medications in this product, can decrease bone marrow function, which may lead to low numbers of red and white blood cells. A low number of red blood cells can lead to anemia. A low number of white blood cells can decrease your body's ability to fight serious, life-threatening infections.<br /><br />These serious side effects occur more frequently in people with advanced HIV disease (AIDS). Seek immediate medical attention if you develop any signs of anemia (such as unusual tiredness, fast breathing, pale skin, fast heartbeat) or signs of infection (such as fever, chills, cough, persistent sore throat). Your doctor will check your blood cell counts while you are taking this medication to decrease the risk of these side effects.<br /><br /> Zidovudine may also cause muscle problems. Seek immediate medical attention if you develop signs of muscle problems (such as wasting or decrease in muscle size, weight loss, muscle weakness/pain/tenderness). Rarely, lamivudine and zidovudine have caused severe (sometimes fatal) liver problems and a certain metabolic problem (lactic acidosis).<br /><br />Tell your doctor right away if you develop symptoms of liver problems (such as persistent nausea, vomiting, stomach/abdominal pain, pale stools, dark urine, yellowing eyes/skin, unusual tiredness), or of lactic acidosis (such as stomach discomfort, nausea, vomiting, fast/difficult breathing, drowsiness, muscle pain, weakness, cold skin). These serious side effects may occur more often in women and obese patients. If you have hepatitis B infection and HIV, you may have a serious worsening of hepatitis symptoms if you stop taking lamivudine.<br /><br />Talk with your doctor before stopping this medication. Your doctor will monitor liver tests for several months after you stop lamivudine. Tell your doctor right away if you develop symptoms of worsening liver problems.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool